What medication is appropriate for an adult with difficulty falling asleep who has no contraindications such as severe liver disease, untreated obstructive sleep apnea, pregnancy, or a history of substance use disorder?

Medication for Sleep-Onset Insomnia in Adults

For adults with difficulty falling asleep, use zolpidem 10 mg, eszopiclone 2–3 mg, zaleplon 10 mg, ramelteon 8 mg, or triazolam 0.25 mg as first-line pharmacologic options, with zolpidem and eszopiclone offering the most robust evidence for sleep-onset improvement. 1, 2

Primary Pharmacologic Options for Sleep Onset

Most Robust Evidence

• Zolpidem 10 mg – The American Academy of Sleep Medicine (AASM) recommends this agent for both sleep onset and maintenance, with moderate-quality evidence demonstrating efficacy in reducing time to fall asleep 1, 2

  • Critical dosing consideration: Women require 5 mg (not 10 mg) due to slower drug clearance; FDA mandates this sex-specific dosing to prevent next-morning impairment 2
  • Older adults also require dose reduction to minimize fall risk and cognitive effects 2

• Eszopiclone 2–3 mg – Provides the strongest evidence base for both acute and long-term treatment beyond 4 weeks, though adverse-event rates are higher than other agents 1, 2

  • Sustained efficacy with moderate-quality evidence distinguishes this from alternatives 2

Targeted Sleep-Onset Agents

• Zaleplon 10 mg – AASM-recommended specifically for sleep-onset insomnia with favorable tolerability, though efficacy data are more limited 1, 2

  • Shortest half-life allows middle-of-night dosing if needed 3

• Ramelteon 8 mg – Melatonin-receptor agonist with AASM recommendation for sleep onset, but significantly less effective than benzodiazepine-receptor agonists 1, 2

  • May be preferred when avoiding controlled substances or in patients concerned about dependence 3

• Triazolam 0.25 mg – Benzodiazepine with AASM recommendation for sleep onset, though benefits approximately equal harms 1

  • Avoid in older adults due to heightened fall and cognitive risks 2

Newer Agent with Favorable Profile

• Suvorexant 10–20 mg – Orexin-receptor antagonist that improves sleep maintenance but also reduces sleep latency, with better tolerability than traditional agents and preservation of natural sleep architecture 1, 2
  • May be preferred when minimizing adverse effects is paramount 2

Agents to Explicitly Avoid

Negative Recommendations from AASM

• Trazodone 50 mg – AASM recommends against use; harms outweigh benefits despite frequent off-label prescribing 1, 2
• Diphenhydramine 50 mg – Not recommended; anticholinergic effects are especially problematic in older adults (cognitive impairment, urinary retention, falls) 1, 2
• Melatonin 2 mg – Insufficient evidence of efficacy for primary insomnia 1, 2
• Tiagabine, tryptophan, valerian – All carry negative recommendations due to lack of efficacy or unfavorable risk-benefit profiles 1, 2

Critical Safety Considerations

Long-Term Risks

• Observational data link hypnotic use to increased risk of dementia, fractures, and major injuries, particularly with benzodiazepines 1, 2
• FDA reports identify cognitive and behavioral changes, including impaired driving, associated with all benzodiazepine-receptor agonists 1, 2

Population-Specific Precautions

• Older adults: Avoid benzodiazepines entirely; use lowest effective doses of Z-drugs with heightened monitoring for falls and confusion 2
• Women: Mandatory dose reduction for zolpidem (5 mg vs. 10 mg in men) due to pharmacokinetic differences 2
• Pregnancy: Case-control studies suggest statistical link between benzodiazepine use in early pregnancy and cleft lip; doxylamine has more reassuring pregnancy data if sedation needed 4

Treatment Duration and Monitoring

• Acute treatment window: Efficacy data support 4–12 weeks for most agents; long-term data beyond this period are limited 1, 2
• Avoid combination therapy: No evidence supports combining hypnotics; concomitant use multiplies safety risks without added benefit 2
• Tolerance development: Patients quickly develop tolerance to benzodiazepine hypnotic effects, with uncertain long-term efficacy 4

Common Pitfalls to Avoid

• Do not prescribe benzodiazepines routinely – Newer agents have superior safety profiles for most patients 3
• Do not continue ineffective therapy – If sleep-onset difficulty persists after 2–4 weeks, reassess underlying causes rather than escalating doses 2
• Do not overlook contraindications – Screen for untreated obstructive sleep apnea, severe liver disease, and substance use history before prescribing any hypnotic 2
• Do not use off-label agents without evidence – Trazodone's widespread use contradicts guideline recommendations against it 1, 2